Cite
HARVARD Citation
Huang, Z. et al. (2021). Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study. Vaccine. 39 (4), pp. 760-766. [Online].